Program
HS-10390
A development code. Also written as “HS-10390 tablet”.
Its studies are mostly in Glomerulonephritis, IGA · Renal Insufficiency, Chronic, led by Hansoh Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 33 open or running | phase 2since Oct 8, 2024 | Jul 4, 2023 | Nov 11, 2027phase 2 · NCT07555054 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 4, 2023First study: phase 1 study in Glomerulonephritis, IGAFirst studyNCT05942625 · 84 planned · China
- Oct 8, 2024Phase 2 study in Glomerulonephritis, IGANCT06635772 · 90 planned · China
- Apr 21, 2026Phase 2 study in Renal Insufficiency, ChronicNCT07555054 · 182 planned · China
Ahead
- Nov 11, 2027Primary completion: phase 2 study in Renal Insufficiency, ChronicNCT07555054
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07555054Renal Insufficiency, Chronic · China | 2 | Not yet recruiting | Nov 11, 2027 | 182 |
| NCT06635772Glomerulonephritis, IGA · China | 2 | Not yet recruiting | Dec 1, 2025 | 90 |
| NCT05942625Glomerulonephritis, IGA · China | 1 | Recruiting | Jun 30, 2024 | 84 |
How it is read
Names in the registry
- “HS-10390”, 4 entries
- “HS-10390 tablet”, 1 entry
Codes read as this program: HS10390.
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 2 studies
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.